



(12) Translation of
European patent specification

(11) NO/EP 2758061 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/7048 (2006.01)
A61K 9/48 (2006.01)
A61K 31/435 (2006.01)
A61K 31/438 (2006.01)
A61K 31/498 (2006.01)
A61K 45/06 (2006.01)
A61P 25/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.04.03
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.11.16
(86)	European Application Nr.	12834382.9
(86)	European Filing Date	2012.09.19
(87)	The European Application's Publication Date	2014.07.30
(30)	Priority	2011.09.20, US, 201161536824 P 2011.09.21, US, 201161537229 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Proprietor	Redhill Biopharma Ltd, 21 Ha'arba'a Street, 64739 Tel Aviv, IL-Israel
(72)	Inventor	FATHI, Reza, 88 North Franklin Turnpike, Hohokus, NJ 07423, US-USA MCLEAN, Patrick, Laughlin, 911/3480 Rue Simpson, Montreal, QC H3G 2N7, CA- Canada LEIGHTON, Harry, Jefferson, 48 Sea Street, Rockport, ME 04856, US-USA
(74)	Agent or Attorney	Bryn Aarflot AS, Postboks 449 Sentrum, 0104 OSLO, Norge

(54)	Title	COMBINATION OF ANTIBIOTICS FOR TREATING AN AUTOIMMUNE DISEASE
(56)	References Cited:	WO-A2-2011/011706 US-A1- 2008 275 063 US-A1- 2011 059 136 US-B1- 7 488 580 BORODY ET AL: "Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars", DIGESTIVE AND LIVER DISEASE, W.B. SAUNDERS, GB, vol. 39, no. 5, 13 April 2007 (2007-04-13) , pages 438-444, XP022045863, ISSN: 1590-8658, DOI: 10.1016/J.DLD.2007.01.008

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Kombinasjon av tre antibiotika som omfatter klaritromycin, rifabutin og
5 klofazimin for anvendelse ved behandling av multippel sklerose.
2. Kombinasjon av tre antibiotika ifølge krav 1, for anvendelse ved behandling av
remitterende multippel sklerose.
- 10 3. Kombinasjon ifølge krav 1, som videre omfatter vitamin D.
4. Kombinasjon ifølge krav 1, som videre omfatter et anti-inflammatorisk middel.
5. Kombinasjon ifølge krav 1, som videre omfatter en cyklinavhengig
15 kinaseinhibitor.
6. Kombinasjon ifølge krav 1, som videre omfatter en aktivert T-celle
transkripsjonsinhibitor.